In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives
Carregando...
Citações na Scopus
33
Tipo de produção
article
Data de publicação
2015
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER JAPAN KK
Autores
MOSTACHIO, Anna Karina
PAEZ, Jorge
CARRILHO, Claudia
Citação
JOURNAL OF INFECTION AND CHEMOTHERAPY, v.21, n.1/Fev, p.114-117, 2015
Resumo
Background: The aim of this study was to evaluate the in vitro susceptibility of MDR gram-negatives bacteria to old drugs such as polymyxin B, minocycline and fosfomycin and new drugs such as tigecycline. Methods: One hundred and fifty-three isolates from 4 Brazilian hospitals were evaluated. Forty-seven Acinetobacter baumannii resistant to carbapenens harboring adeB, bla(OxA23), bla(OxA51), bla(OxA143) 23, and bla(IMP) genes, 48 Stenotrophomonas maltophilia including isolates resistant to levofloxacin and/or trimethoprim-sulfamethoxazole harboring sul-1, sul-2 and qnr(MR) and 8 Serratia marcescens and 50 Klebsiella pneumoniae resistant to carbapenens harboring bla(KPC-2) were tested to determine their minimum inhibitory concentrations (MICs) by microdilution to the following drugs: minocycline, ampicillin-sulbactam, tigecycline, and polymyxin B and by agar dilution to fosfomycin according with breakpoint criteria of CLSI and EUCAST (fosfomycin). In addition, EUCAST fosfomycin breakpoint for Pseudomonas spp. was applied for Acinetobacter spp and S. maltophilia, the FDA criteria for tigecycline was used for Acinetobacter spp and S. maltophilia and the Pseudomonas spp polymyxin B CLSI criterion was used for S. maltophilia. Results: Tigecycline showed the best in vitro activity against the MDR gram-negative evaluated, followed by polymyxin B and fosfomycin. Polymyxin B resistance among K. pneumoniae was detected in 6 isolates, using the breakpoint of MIC > 8 ug/mL. Two of these isolates were resistant to tigecycline. Minocycline was tested only against S. maltophilia and A. baumannii and showed excellent activity against both. Conclusions: Fosfomycin seems to not be an option to treat infections due to the A. baumannii and S. maltophilia isolates according with EUCAST breakpoint, on the other hand, showed excellent activity against S. marcescens and K. pneumoniae. (C) 2014, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.
Palavras-chave
Polymyxin B, Fosfomycin, Tigecycline, Minocycline, MDR gram-negatives
Referências
- Ahmed NH, 2012, BMC RES NOTES, V3, P215
- Behera B, 2009, INDIAN J MED RES, V129, P446
- Brooke JS, 2012, CLIN MICROBIOL REV, V25, P2, DOI [10.1128/CMR.00019-11, 10.1128/CMR.00019-11]
- Chen Y, 2011, J ANTIMICROB CHEMOTH, V66, P1255, DOI 10.1093/jac/dkr082
- Cho YS, 2012, INFECTION, V40, P27, DOI 10.1007/s15010-011-0192-7
- Clinical and Laboratory Standards Institute (CLSI), 2013, PERF STAND ANT SUSC
- Czihal P, 2012, ACS CHEM BIOL, V7, P1281, DOI 10.1021/cb300063v
- EUCAST, 2013, BREAKP TABL INT MICS
- Falagas ME, 2010, LANCET INFECT DIS, V10, P43, DOI 10.1016/S1473-3099(09)70325-1
- FDA. U.S. Food and Drug Administration, TYG TIG INJ
- Fuste E, 2012, FUTURE MICROBIOL, V7, P781, DOI [10.2217/fmb.12.40, 10.2217/FMB.12.40]
- Gales AC, 2011, J ANTIMICROB CHEMOTH, V66, P2070, DOI 10.1093/jac/dkr239
- Higgins PG, 2009, ANTIMICROB AGENTS CH, V53, P5035, DOI 10.1128/AAC.00856-09
- Hu LF, 2011, INT J ANTIMICROB AG, V37, P230, DOI 10.1016/j.ijantimicag.2010.10.025
- Karageorgopoulos DE, 2012, J ANTIMICROB CHEMOTH, V67, P255, DOI 10.1093/jac/dkr466
- Ku K, 2012, AM J INFECT CONTROL, V40, P983, DOI 10.1016/j.ajic.2011.12.014
- Liao CH, 2008, INT J ANTIMICROB S3, V32, P192
- Lim TP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018485
- Lin L, 2009, INT J ANTIMICROB AG, V33, P27, DOI 10.1016/j.ijantimicag.2008.06.027
- Livermore DM, 2009, J ANTIMICROB CHEMOTH, V64, P29, DOI 10.1093/jac/dkp255
- Livermore DM, 2011, INT J ANTIMICROB AG, V37, P415, DOI 10.1016/j.ijantimicag.2011.01.012
- Mendes RE, 2007, J CLIN MICROBIOL, V45, P544, DOI 10.1128/JCM.01728-06
- Mostachio AK, 2012, INT J ANTIMICROB AG, V39, P396, DOI 10.1016/j.ijantimicag.2012.01.021
- Nicodemo AC, 2004, J ANTIMICROB CHEMOTH, V53, P604, DOI 10.1093/jac/dkh128
- Paksu MS, 2012, INT J ANTIMICROB AG, V40, P140, DOI 10.1016/j.ijantimicag.2012.04.010
- Perdigao-Neto LV, 2013, ANTIMICROBIAL AGENTS, V57
- Rumbo C, 2013, ANTIMICROB AGENTS CH, V57, P5247, DOI 10.1128/AAC.00730-13
- Sanchez MB, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-148
- Toleman MA, 2006, MICROBIOL MOL BIOL R, V70, P296, DOI 10.1128/MMBR.00048-05
- Woodford N, 2006, INT J ANTIMICROB AG, V27, P351, DOI 10.1016/j.ijantimicag.2006.01.004